Committed to Advancing TAVR

ABOUT HLT

Our mission is to advance TAVR through innovation, technologies and procedural techniques designed to achieve better, more predictable patient outcomes and improve quality of life for TAVR patients.

Resourced for Innovation

HLT is a part of the Bracco Group, an Italy-based, multinational healthcare company operating in over 100 countries worldwide with revenues exceeding €1.3B. Bracco invests a significant amount of its resources in research and innovation across its portfolio of companies to improve patient outcomes and optimize treatment procedures.

World Class Expertise

With global headquarters in Minnesota, USA, HLT employs highly experienced healthcare and device industry professionals working in a creative, collaborative and entrepreneurial environment.

Focused Agility

We pride ourselves on innovating for specific unmet clinical needs and rapidly responding to technological change.

The opportunity

HLT is re-imaging and re-designing TAVR technology to further optimize the clinical and procedural performance of today’s TAVR solutions.

To drive TAVR therapy forward, we believe:

  1. Valve technology must conform to the native valve anatomy. The Meridian® II Valve is designed to conform to the native anatomy with intra-annular placement and flexible, commissural support of the leaflets. These features are intended to reduce stress and extend durability.
  2. Additional clinical needs must be met. As transcatheter valve therapy gains broader clinical acceptance and indications expand, opportunities remain to improve valve design and enhance procedural control; particularly in optimizing implant position. Our goal is to provide the flexibility and control for the best possible transcatheter aortic valve replacement given the unique anatomical challenges of each patient with aortic stenosis.

The Meridian® II Valve and Pathfinder® Delivery System are intended to provide:

Procedural Flexibility

Reposition the valve and assess full hemodynamic function prior to final valve release.

Durability by Design

Achieve coaptation and reduced commissure stress, regardless of native annulus shape.

Fully Retrievable

Retrieve the valve prior to final release for better outcomes and lower complications.

Low-profile Design

Reposition the valve and assess full hemodynamic function prior to final valve release.

Explore the Meridian II Valve

About transcatheter aortic valve replacement (TAVR) and aortic stenosis

Transcatheter aortic valve replacement treats one of the most common heart valve diseases, aortic stenosis, which is a narrowing of the aortic valve that obstructs blood flow from the heart.

Watch the full animation

Surgical aortic valve replacement (SAVR) is the current standard treatment for patients with severe symptomatic aortic stenosis. However a less-invasive approach, transcatheter aortic valve replacement (TAVR), is now considered as a way to replace the diseased aortic valve without open heart surgery for this patient population.
The TAVR procedure involves making a small incision in the upper leg and navigating a replacement valve into the heart.

About the RADIANT trial

The RADIANT trial is a prospective, non-randomized, single-arm, multicenter study that will enroll patients with severe aortic valve stenosis and evaluate safety and performance outcomes of HLT’s Meridian® Valve and Pathfinder® II Delivery System.

Learn more
M